What is CJC-1295 DAC?

CJC-1295 DAC is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) that has been modified with a Drug Affinity Complex (DAC) for extended binding to albumin, intended solely for research applications.

How does CJC-1295 DAC differ from other GHRH analogs in research?

The primary distinguishing feature of CJC-1295 DAC is its conjugation with a DAC, which significantly prolongs its effective research half-life by enhancing its binding to endogenous albumin, allowing for sustained GHRH receptor activation in experimental settings compared to shorter-acting analogs.

What is the mechanism of action of CJC-1295 DAC in research?

In research models, CJC-1295 DAC functions by binding to GHRH receptors on pituitary somatotrophs, mimicking natural GHRH to stimulate the synthesis and secretion of growth hormone, with its DAC conjugation extending the duration of this stimulatory effect.

For what type of research is CJC-1295 DAC typically used?

CJC-1295 DAC is utilized in fundamental research to investigate the mechanisms of growth hormone regulation, pituitary function, and the potential impact of sustained GHRH receptor activation in various preclinical models.

Are there any human studies registered for CJC-1295 DAC?

As of the latest review, there are no registered human studies involving CJC-1295 DAC listed on ClinicalTrials.gov, indicating its current status as a compound exclusively for laboratory research.

How many scientific publications are available on CJC-1295 DAC?

Currently, there is 1 publication indexed in PubMed specifically pertaining to CJC-1295 DAC, reflecting its emergent and specialized presence in the scientific literature.

What are the storage requirements for CJC-1295 DAC in a research laboratory?

CJC-1295 DAC, like most research peptides, typically requires storage at low temperatures (e.g., -20°C or colder) in a desiccated state to maintain its stability and potency for experimental use, with specific instructions usually provided by the supplier.

Is CJC-1295 DAC intended for human consumption or therapeutic use?

Absolutely not. CJC-1295 DAC is strictly for research purposes only and is not intended for human consumption, diagnostic, therapeutic, or any other application involving humans or animals. Its use must be confined to well-controlled laboratory environments by trained personnel.

CJC-1295 DAC growth-hormone research: Reference

CJC-1295 DAC is an investigational growth-hormone-releasing hormone (GHRH) analog characterized by its unique conjugation with a Drug Affinity Complex (DAC), which facilitates extended binding to albumin and thereby prolongs its effective research activity. This design feature aims to provide sustained stimulation of growth hormone secretion from the anterior pituitary in experimental models, offering a tool for studies exploring pulsatile GHRH signaling and its implications. Researchers utilize CJC-1295 DAC to investigate endogenous growth hormone dynamics and related physiological processes in controlled laboratory settings.

As a compound primarily explored within fundamental scientific inquiry, CJC-1295 DAC currently has 1 publication indexed in PubMed and has not been registered in any studies on ClinicalTrials.gov, highlighting its nascent stage within the broader research landscape and its strict designation as a research-use-only chemical for laboratory applications.

The Foundation: Growth Hormone Releasing Hormone (GHRH) and its Research Significance

Growth Hormone Releasing Hormone (GHRH), also known as somatocrinin, stands as a pivotal neurohormone within the hypothalamic-pituitary axis, playing a fundamental role in the intricate regulation of growth hormone (GH) secretion. Synthesized and released from the arcuate nucleus of the hypothalamus, GHRH acts directly on somatotroph cells within the anterior pituitary gland, stimulating both the synthesis and pulsatile release of GH. This endogenous peptide hormone operates through specific GHRH receptors (GHRH-R) on the surface of pituitary somatotrophs, initiating a cascade of intracellular signaling events that culminate in the exocytosis of pre-formed GH stores and the subsequent transcription of new GH mRNA. The pulsatile nature of GHRH release is critical for maintaining the physiological rhythm of GH secretion, which in turn influences a broad spectrum of metabolic and physiological processes throughout an organism’s lifespan.

The research significance of GHRH extends across numerous scientific disciplines, driven by its central role in controlling the somatotropic axis. Investigating GHRH and its analogs allows researchers to dissect the complex interplay between hypothalamic signaling, pituitary function, and peripheral metabolic regulation. Studies focusing on GHRH contribute to a deeper understanding of growth and development, body composition, energy metabolism, and various endocrine disorders. For instance, models of GH deficiency or excess can often be traced back to dysregulation within the GHRH-GH-IGF-1 axis, providing critical avenues for research into potential interventions. Furthermore, the transient and highly regulated nature of natural GHRH release makes its synthetic analogs valuable tools for probing dynamic physiological responses in research settings.

Understanding the precise mechanisms by which GHRH stimulates GH release is paramount for developing sophisticated research tools and models. The binding of GHRH to its receptor activates adenylate cyclase, leading to an increase in intracellular cyclic AMP (cAMP) levels. Elevated cAMP then activates protein kinase A (PKA), which phosphorylates various intracellular targets, including calcium channels and transcription factors, ultimately promoting GH synthesis and secretion. This intricate signaling pathway ensures that GH release is tightly controlled, responding to a myriad of internal and external cues such as sleep-wake cycles, nutrient availability, and stress. Researchers leverage this knowledge to design experiments that manipulate the GHRH pathway, aiming to elucidate its roles in maintaining physiological homeostasis and adapting to environmental challenges in various animal and cellular models.

The GHRH-GH-IGF-1 Axis in Research

The cascading hormonal axis initiated by GHRH is often referred to as the GHRH-GH-IGF-1 axis. Once GH is secreted from the pituitary, it circulates throughout the bloodstream and exerts its effects both directly and indirectly. A significant portion of GH’s anabolic and metabolic actions are mediated indirectly through insulin-like growth factor 1 (IGF-1), which is primarily produced in the liver in response to GH stimulation, though local IGF-1 production occurs in many tissues. IGF-1 then acts as an endocrine hormone, binding to its own receptors on target cells to mediate growth-promoting effects, protein synthesis, and cellular proliferation. This feedback loop is also crucial, as elevated IGF-1 levels can provide negative feedback to both the hypothalamus (inhibiting GHRH release) and the pituitary (inhibiting GH release and increasing somatostatin secretion). Research models employing GHRH analogs often focus on quantifying changes across all components of this axis to understand systemic effects.

The importance of this axis for research cannot be overstated. By studying compounds that modulate GHRH receptor activity, researchers can investigate:

The physiological regulation of growth and development in various animal models.
Mechanisms underlying metabolic disorders, such as insulin resistance and lipid metabolism dysfunction, in preclinical settings.
The role of GH in tissue regeneration and repair processes following injury or disease in research models.
Neuroendocrine pathways involved in aging, muscle mass maintenance, and bone density regulation in experimental organisms.
The impact of sustained GH elevation on cellular proliferation and differentiation in *in vitro* and *in vivo* studies.

These research avenues highlight the utility of GHRH and its analogs, such as CJC-1295 DAC, as invaluable tools for expanding our scientific understanding of fundamental biological processes and disease pathology.

CJC-1295 DAC: A GHRH Analog with Enhanced Albumin Binding

CJC-1295 DAC, often referred to as CJC-1295 with DAC, represents a significant advancement in the field of peptide research, specifically designed as a synthetic analog of Growth Hormone Releasing Hormone (GHRH) with substantially enhanced pharmacokinetic properties. While the native GHRH peptide has a very short half-life in circulation due to rapid enzymatic degradation and renal clearance, CJC-1295 DAC was engineered to overcome these limitations through its unique structural modification. This compound consists of the bioactive sequence of GHRH (a 30-amino acid peptide) conjugated with a Drug Affinity Complex (DAC), a proprietary technology that facilitates extended binding to endogenous albumin. This albumin-binding strategy is the cornerstone of its prolonged action, setting it apart from unmodified GHRH or other short-acting GHRH analogs in research applications.

The precise molecular architecture of CJC-1295 DAC is critical to its function. It incorporates a modified GHRH peptide sequence that retains high affinity for the GHRH receptor on pituitary somatotrophs, ensuring its biological activity is preserved. The key differentiator, however, is the covalent attachment of a Drug Affinity Complex, which forms a stable yet reversible bond with circulating albumin. Albumin, the most abundant protein in plasma, acts as a natural carrier for many endogenous compounds and exogenous agents, effectively shielding conjugated molecules from rapid enzymatic degradation and reducing their glomerular filtration rate in the kidneys. This protective association with albumin markedly extends the systemic half-life of CJC-1295 DAC, allowing for a more sustained presence and activity in research models compared to the rapid clearance observed with traditional GHRH peptides.

Structural and Pharmacokinetic Advantages

The primary advantage of CJC-1295 DAC for research lies in its altered pharmacokinetic profile. Traditional GHRH or first-generation synthetic GHRH analogs typically exhibit plasma half-lives measured in minutes, necessitating frequent administration in research protocols to maintain consistent stimulation of GH release. In contrast, the albumin-binding capability of CJC-1295 DAC extends its half-life to several days, transforming the practicality of longitudinal studies in animal models. This extended duration of action enables researchers to investigate the chronic effects of sustained GHRH receptor stimulation without the confounding variables introduced by multiple daily injections or constant infusions, which can perturb research subjects and complicate experimental design. The stability conferred by DAC also means the peptide is less susceptible to degradation by ubiquitous proteases, further contributing to its enhanced bioavailability and prolonged therapeutic window in research settings.

Researchers utilizing CJC-1295 DAC can expect a more predictable and consistent exposure to the GHRH analog, which is invaluable for studies requiring steady GHRH receptor activation over prolonged periods. This characteristic is particularly beneficial when examining slow-acting biological processes such as long-term metabolic adaptations, tissue regeneration, or developmental changes in experimental models. The consistency provided by its extended half-life streamlines experimental protocols, potentially reducing the number of administrations required and minimizing handling stress on research animals, thereby improving the welfare of subjects and the reliability of study outcomes. This makes CJC-1295 DAC a preferred agent for investigations into the sustained modulation of the GH-IGF-1 axis, offering a more robust and experimentally tractable approach compared to its predecessors. For further understanding of peptide research, explore what research peptides are.

Mechanism of Action: Prolonged Stimulation of Growth Hormone Release in Research Models

The mechanism of action for CJC-1295 DAC fundamentally mirrors that of endogenous Growth Hormone Releasing Hormone (GHRH), yet with a crucial pharmacokinetic modification that confers prolonged activity within research models. Upon administration, CJC-1295 DAC circulates in the bloodstream and, due to its Drug Affinity Complex (DAC) conjugation, forms a reversible complex with plasma albumin. This albumin-bound form acts as a circulating reservoir, slowly releasing the active GHRH analog into the unbound fraction. The unbound CJC-1295 DAC then travels to the anterior pituitary gland, where it selectively binds to and activates the GHRH receptors (GHRH-R) located on the surface of somatotroph cells. This highly specific binding initiates a cascade of intracellular events that are characteristic of GHRH signaling, but sustained over a significantly extended period.

Activation of the GHRH receptor by CJC-1295 DAC triggers a G-protein coupled receptor (GPCR) pathway. Specifically, it couples to Gs proteins, leading to the activation of adenylate cyclase. This enzyme then catalyzes the conversion of adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP), causing a rapid increase in intracellular cAMP concentrations within the somatotrophs. Elevated cAMP levels, in turn, activate protein kinase A (PKA), a key enzyme that phosphorylates various target proteins. These phosphorylated proteins include components of the calcium signaling pathway and transcription factors crucial for growth hormone synthesis. The influx of calcium ions into the somatotrophs, alongside the activation of PKA, synergistically promotes the exocytosis of pre-formed growth hormone vesicles, leading to an acute release of GH into the systemic circulation. Simultaneously, PKA activation enhances the transcription of the GH gene, thereby replenishing GH stores for subsequent release.

Sustained Pulsatile Secretion and Downstream Effects

The distinguishing feature of CJC-1295 DAC’s mechanism in research models is its capacity for prolonged stimulation of growth hormone release. Unlike unmodified GHRH which elicits a transient burst, the slow-release kinetics facilitated by the DAC-albumin interaction ensure that a steady concentration of active CJC-1295 DAC remains available to the pituitary for an extended duration. This results in a sustained, yet still physiologically pulsatile, pattern of GH secretion over several days. The maintenance of this pulsatile release is critical, as the periodicity of GH secretion has been shown to be biologically significant in mediating GH’s diverse physiological effects. This sustained physiological stimulation allows researchers to investigate the long-term impact of amplified GH signaling without the need for frequent dosing, providing a more stable experimental environment for observing physiological adaptations.

The prolonged elevation of circulating growth hormone levels, induced by CJC-1295 DAC in research models, subsequently drives downstream effects within the GH-IGF-1 axis. High GH concentrations stimulate the liver to produce and secrete Insulin-like Growth Factor 1 (IGF-1), which acts as a primary mediator of many of GH’s anabolic and growth-promoting actions. IGF-1 then circulates and binds to IGF-1 receptors on various target tissues, promoting cellular proliferation, protein synthesis, and tissue growth. Beyond IGF-1, GH also exerts direct metabolic effects on adipose tissue, muscle, and other organs. Therefore, the prolonged stimulation afforded by CJC-1295 DAC allows researchers to comprehensively evaluate the chronic impact on body composition, metabolic parameters, and organ function in experimental animals, providing valuable insights into the roles of sustained GH/IGF-1 signaling in health and disease models. For more detailed information on its action, refer to CJC-1295 DAC Mechanism of Action.

The Drug Affinity Complex (DAC) Strategy for Extended Half-Life in Research Peptides

The Drug Affinity Complex (DAC) technology represents a sophisticated pharmacokinetic enhancement strategy specifically designed to extend the systemic half-life of research peptides and small molecules. This innovative approach addresses a common limitation of many peptide-based compounds: their inherent susceptibility to rapid enzymatic degradation and swift renal clearance, which severely limits their duration of action and necessitates frequent administration in research protocols. The DAC strategy overcomes these challenges by engineering a chemical modification onto the peptide that facilitates a strong, yet reversible, binding to endogenous albumin, the most abundant protein in mammalian plasma. This albumin conjugation effectively transforms the peptide into a long-acting agent, greatly improving its utility for longitudinal studies in various research models.

At its core, the DAC strategy leverages the natural role of albumin as a carrier protein within the circulatory system. Albumin possesses multiple binding sites for a diverse range of endogenous and exogenous molecules, and its large molecular weight (approximately 66.5 kDa) prevents it from being rapidly filtered by the kidneys. By chemically conjugating a peptide, such as CJC-1295, with a DAC moiety, the resulting complex gains the ability to associate with circulating albumin. This association significantly increases the apparent molecular weight of the peptide, thereby reducing its renal clearance. Furthermore, being bound to albumin can protect the peptide from proteolytic enzymes present in the bloodstream, effectively shielding it from degradation and prolonging its functional integrity. This combination of reduced clearance and increased stability dramatically extends the systemic residence time of the active compound.

Mechanisms of Albumin Binding and Release Kinetics

The interaction between the DAC moiety and albumin is carefully designed to be reversible, ensuring that the active peptide is slowly released over time from the albumin reservoir. This dynamic binding and unbinding equilibrium allows for a sustained low concentration of the free, biologically active peptide to be continuously available to its target receptors. The kinetics of this release can be tuned through specific modifications to the DAC moiety, influencing the duration and profile of the peptide’s activity. For CJC-1295 DAC, this engineered release profile is critical for maintaining a consistent, yet not overwhelming, stimulation of GHRH receptors, thereby inducing a more physiological pattern of growth hormone release than would be possible with a rapid bolus injection of a short-acting analog. The ability to control these release kinetics makes the DAC platform incredibly versatile for developing long-acting research tools.

The practical implications of the DAC strategy for peptide research are profound. Researchers can achieve prolonged exposure of their experimental models to the peptide of interest with significantly reduced dosing frequency. This not only minimizes stress on research animals and improves animal welfare but also simplifies experimental design and logistics, especially for long-term studies. Reduced dosing frequency also means a more consistent drug exposure, leading to more reproducible and reliable research outcomes by avoiding peaks and troughs in peptide concentration that could confound results. The DAC technology transforms peptides from short-lived signals into sustained modulators, opening new avenues for investigating chronic physiological processes, developmental trajectories, and the long-term effects of endocrine manipulations in preclinical research. This innovative approach contributes to the overall efficiency and scientific rigor of peptide-based investigations.

Investigational Utility: Exploring Endogenous Growth Hormone Dynamics with CJC-1295 DAC

CJC-1295 DAC presents a unique and powerful tool for researchers aiming to explore the intricate dynamics of the endogenous growth hormone (GH) axis within various biological models. Its primary investigational utility stems from its ability to provide a sustained and amplified, yet physiologically relevant, stimulation of GHRH receptors, leading to prolonged GH release. Unlike the transient effects of unmodified GHRH or rapid-acting analogs, CJC-1295 DAC offers a stable pharmacokinetic profile, allowing for consistent modulation of the somatotropic axis over extended periods. This characteristic is invaluable for dissecting the long-term regulatory mechanisms of GH and its downstream effector, IGF-1, in controlled experimental settings. Researchers can leverage this sustained action to investigate how chronic GHRH receptor activation impacts cellular processes, tissue growth, and systemic metabolic homeostasis.

One significant area of investigation where CJC-1295 DAC proves particularly useful is in models of growth hormone deficiency or insufficiency. By consistently stimulating endogenous GH production and release, researchers can study the potential for restoring normal growth patterns, improving body composition (e.g., lean mass accretion vs. adipose tissue reduction), and ameliorating metabolic dysregulation associated with suboptimal GH levels. This provides insights into the plasticity of the GH axis and the capacity of the pituitary to respond to sustained GHRH signaling in different physiological states. Such studies are critical for understanding the underlying pathophysiology of GH-related disorders and exploring the fundamental requirements for maintaining GH-dependent functions in experimental organisms, without ever implying human use or therapeutic intent.

Research Areas and Experimental Advantages

Beyond deficiency models, CJC-1295 DAC offers distinct experimental advantages for probing broader aspects of metabolism, aging, and tissue biology. Its sustained action allows researchers to:

Investigate Metabolic Regulation: Study the chronic effects of elevated GH/IGF-1 on glucose homeostasis, lipid metabolism, and insulin sensitivity in animal models, contributing to our understanding of metabolic syndromes and type 2 diabetes.
Explore Body Composition: Analyze changes in lean body mass, fat mass distribution, and bone mineral density over time, providing insights into the anabolic and catabolic balance influenced by the GH axis.
Delve into Aging Processes: Research the role of GH/IGF-1 signaling in age-related decline of muscle mass (sarcopenia), bone health, and cognitive function in aged animal models, helping to unravel complex aging mechanisms.
Examine Tissue Repair and Regeneration: Study how sustained GH stimulation influences wound healing, tissue repair after injury, or organ regeneration processes in preclinical models, focusing on cellular proliferation and differentiation.
Characterize Neuroendocrine Interactions: Probe the feedback loops and interactions between the GHRH-GH-IGF-1 axis and other endocrine systems, such as the thyroid or adrenal axes, under conditions of prolonged GHRH receptor activation.

The ability of CJC-1295 DAC to provide prolonged exposure to GHRH receptor activation without the need for frequent interventions significantly enhances the feasibility and reliability of these complex, long-term research investigations. It minimizes experimental variability introduced by fluctuating peptide levels and reduces animal handling stress, thereby yielding more robust and interpretable data on the sustained biological impact of GH dynamics. The consistency in GH output that CJC-1295 DAC can induce provides a controlled environment for observing physiological adaptations and pathological developments in response to altered GH signaling.

Experimental Design Considerations for CJC-1295 DAC Studies

Designing robust and interpretable research studies utilizing CJC-1295 DAC requires careful consideration of several critical experimental parameters, given its unique prolonged-action pharmacokinetic profile. Researchers must account for the extended half-life of CJC-1295 DAC, which profoundly influences dosing frequency, study duration, and the timing of data collection. The choice of appropriate research models, formulation of the peptide, route of administration, and selection of relevant endpoints are all crucial for generating scientifically sound data. A well-constructed experimental design not only maximizes the scientific yield but also ensures ethical treatment of research subjects and optimizes resource utilization within the laboratory setting.

Key Elements of Experimental Design

Research Model Selection

The selection of an appropriate research model is paramount. CJC-1295 DAC is intended for *research-use-only* and its studies are typically conducted in *in vitro* cellular systems or *in vivo* animal models. The choice of animal model (e.g., rodent, lagomorph, or larger mammalian models) should be dictated by the specific research question, considering factors such as species-specific GHRH receptor characteristics, baseline GH/IGF-1 axis activity, genetic background, and ease of handling. For example, studies investigating metabolic changes might benefit from models prone to diet-induced obesity, while studies on bone density might utilize specific aging models. It is imperative to consult relevant literature to identify models that are biologically relevant and validated for similar types of GHRH or GH research.

Dosing Strategy and Administration

Given CJC-1295 DAC’s extended half-life, a distinct dosing strategy is required compared to short-acting peptides. Instead of daily or multiple-daily injections, CJC-1295 DAC can typically be administered less frequently, sometimes weekly or bi-weekly, depending on the desired level and duration of GHRH receptor stimulation. Determining the optimal dose involves:

Literature Review: Examining existing studies (even if limited for CJC-1295 DAC itself, general GHRH analog literature can provide guidance on starting points).
Pilot Studies: Conducting preliminary dose-response studies in a small cohort of animals to establish effective concentrations and observe pharmacokinetic/pharmacodynamic profiles (e.g., GH/IGF-1 elevation over time).
Frequently Asked Questions

What is CJC-1295 DAC?

CJC-1295 DAC is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) that has been modified with a Drug Affinity Complex (DAC) for extended binding to albumin, intended solely for research applications.

How does CJC-1295 DAC differ from other GHRH analogs in research?

The primary distinguishing feature of CJC-1295 DAC is its conjugation with a DAC, which significantly prolongs its effective research half-life by enhancing its binding to endogenous albumin, allowing for sustained GHRH receptor activation in experimental settings compared to shorter-acting analogs.

What is the mechanism of action of CJC-1295 DAC in research?

In research models, CJC-1295 DAC functions by binding to GHRH receptors on pituitary somatotrophs, mimicking natural GHRH to stimulate the synthesis and secretion of growth hormone, with its DAC conjugation extending the duration of this stimulatory effect.

For what type of research is CJC-1295 DAC typically used?

CJC-1295 DAC is utilized in fundamental research to investigate the mechanisms of growth hormone regulation, pituitary function, and the potential impact of sustained GHRH receptor activation in various preclinical models.

Are there any human studies registered for CJC-1295 DAC?

As of the latest review, there are no registered human studies involving CJC-1295 DAC listed on ClinicalTrials.gov, indicating its current status as a compound exclusively for laboratory research.

How many scientific publications are available on CJC-1295 DAC?

Currently, there is 1 publication indexed in PubMed specifically pertaining to CJC-1295 DAC, reflecting its emergent and specialized presence in the scientific literature.

What are the storage requirements for CJC-1295 DAC in a research laboratory?

CJC-1295 DAC, like most research peptides, typically requires storage at low temperatures (e.g., -20°C or colder) in a desiccated state to maintain its stability and potency for experimental use, with specific instructions usually provided by the supplier.

Is CJC-1295 DAC intended for human consumption or therapeutic use?

Absolutely not. CJC-1295 DAC is strictly for research purposes only and is not intended for human consumption, diagnostic, therapeutic, or any other application involving humans or animals. Its use must be confined to well-controlled laboratory environments by trained personnel.

Scientific References

PubMed: CJC-1295 DAC

ClinicalTrials.gov: CJC-1295 DAC

All information from Royal Peptide Labs is provided for in-vitro laboratory and research use only — not for human, veterinary, diagnostic, or therapeutic use.